R&D channel feed – Endpoints News

R&D channel feed

J&J and Legend say Carvykti improved survival in earlier-line multiple myeloma

10 months ago

Four key weight loss readouts to watch at #EASD24

10 months ago

Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M

10 months ago

Corrected: Boehringer Ingelheim, Gubra put a second candidate into the obesity race

10 months ago

Aerovate plans to lay off nearly all employees after trial failure

10 months ago

Eisai takes over development of ADC after Bristol Myers ends $650M collaboration

10 months ago

Dianthus teases preclinical data for autoimmune drug as it starts clinical trials

10 months ago

EMA's CHMP recommends 10 new drugs as Pierre Fabre overactive bladder med wins approval

10 months ago

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

10 months ago

Lykos takes another hit as ICER lays out 'insufficient' evidence for MDMA-based treatment

10 months ago

To tackle a deadly brain disease, scientists devise small but charming epigenetic editing tool

10 months ago

Biogen is pursuing more dealmaking this year, with plans to spend up to $8B

10 months ago

Silence reports Phase 1 data from rare blood disorder trial

10 months ago

Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail

10 months ago

FDA rejects Daiichi Sankyo's HER3 ADC, a blow to quick approval plans for Merck partnership

10 months ago

Scientists unveil new way to make large changes to genes, and no CRISPR is required

10 months ago

Savara’s rare lung disease treatment passes Phase 3

10 months ago

Novo Nordisk takes $816M writedown after Phase 3 fail in chronic kidney disease

10 months ago

Moderna's updated RSV vaccine disappoints with only 50% efficacy

10 months ago

Zealand rides obesity wave with $1B raise to advance amylin drug and look for a partner

10 months ago

Lyell reports patient death, early responses in solid tumor CAR-T trial

10 months ago

Arrowhead shelves one cardiometabolic drug candidate, focuses on another

10 months ago

Lilly becomes the latest pharma to tap OpenAI for help, this time for antibiotic work

10 months ago

Can CRISPR be given twice? Small study from Intellia suggests it can

10 months ago

First page Previous page 35 36 373839 40 41 Next page Last page